Surrozen, Inc.
NASDAQ:SRZNBiotechnology
-$1.14 today
- Market cap
- $237.33M
- Beta
- 0.51
- P/E (TTM)
- -0.7
- EPS (TTM)
- -$31.29
Volume 0.31M
Average 0.11M
SRZN Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Surrozen, Inc.NASDAQ: SRZN
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development grows, but more slowly than its trailing trend
Q1 FY2026 research & development of $9.33M rose 42.2% year over year, behind the +45.7% change in trailing-twelve-month research & development. Sequentially, it rose 3.7% from the prior quarter. Over 3 fiscal years it compounded at -7.4% a year.
Context
- Research & development amounted to 844.5% of revenue in FY2025, up 646.2 pp from a year earlier.
- Research & development increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from +42.2% toward the trailing-twelve-month pace of +45.7%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 29.37M USD
- Year-over-year change
- +39.0%
- 4-year CAGR
- -5.5%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 29.37M | +39.0% |
| FY2024 | 2024-12-31 | 21.13M | -22.4% |
| FY2023 | 2023-12-31 | 27.23M | -26.4% |
| FY2022 | 2022-12-31 | 37.01M | +0.4% |
| FY2021 | 2021-12-31 | 36.88M | — |
Research & Development vs competitors
How SRZN compares with its peers on the latest reported figures
- SRZN's LTM Mar 2026 research & development of $32.14M is the 5th highest of the 8 companies compared; the peer median is $32.45M.
- Its year-over-year change of +45.7% is the 3rd highest of 8, against a peer median of +11.2%.
- Research & development amounts to 428.8% of revenue for SRZN, versus a peer median of 274.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $41.33M | -11.2% | -6.2% | 274.8% | |
| LTM Mar 2026 | $38.53M | -58.1% | — | 31.1% | |
IRDOpus Genetics, Inc. | LTM Mar 2026 | $33.44M | +11.2% | +29.0% | 279.0% |
| LTM Mar 2026 | $32.45M | -22.6% | +7.0% | — | |
| LTM Mar 2026 | $32.14M | +45.7% | -7.4% | 428.8% | |
| LTM Mar 2026 | $20.26M | +102.3% | +57.1% | — | |
| LTM Mar 2026 | $20.04M | +101.3% | -58.6% | — | |
| LTM Mar 2026 | $15.76M | +21.0% | +38.5% | — | |
| Peer median (excluding SRZN) | $32.45M | +11.2% | +18.0% | 274.8% | |
Competitors are the stored peer set for SRZN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 12.5M | 0 | 10.66M | 3.48M |
| Cost of Revenue | 3.3M | 3.27M | 27.23M | 0 | 537K |
| Gross Profit | (3.3M) | 9.23M | (27.23M) | 10.66M | 2.94M |
| Gross Margin | — | 73.8% | — | 100.0% | 84.6% |
| Research & Development | 36.88M | 37.01M | 27.23M | 21.13M | 29.37M |
| Selling, General & Admin | 14.21M | 19.83M | 15.8M | 15.06M | 16.2M |
| Operating Expenses | 51.09M | 53.57M | 18.55M | 36.19M | 45.03M |
| Depreciation & Amortization | 3.3M | 1.96M | 1.91M | 1.44M | 537K |
| EBITDA | (51.35M) | (34.05M) | (41.13M) | (62.12M) | (241.49M) |
| EBITDA Margin | — | -272.4% | — | -583.0% | -6945.3% |
| Operating Income | (54.39M) | (44.34M) | (45.78M) | (25.54M) | (42.09M) |
| Operating Margin | — | -354.7% | — | -239.7% | -1210.6% |
| Interest Income | 72K | 781K | 2.34M | 1.69M | 3.02M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (257K) | 8.34M | 2.74M | (38.03M) | (199.93M) |
| Income Before Tax | (54.65M) | (36M) | (43.04M) | (63.56M) | (242.03M) |
| Pre-Tax Margin | — | -288.0% | — | -596.6% | -6960.8% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (52.51M) | (36M) | (43.04M) | (63.56M) | (242.03M) |
| Net Margin | — | -288.0% | — | -596.6% | -6960.8% |
| EPS (Basic) | (23.40) | (15.55) | (21.33) | (21.67) | (32.37) |
| EPS (Diluted) | (23.40) | (15.55) | (21.33) | (21.67) | (32.37) |
| Weighted Avg Shares | 2.34M | 2.31M | 2.02M | 2.93M | 7.48M |
| Weighted Avg Shares (Diluted) | 2.34M | 2.31M | 2.02M | 2.93M | 7.48M |
Surrozen, Inc.
NASDAQ:SRZN
Intrinsic Alpha fair value
Locked
Current Price
$31.74
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.